OBJECTIVES: p21 (WAF1/Cip1/CDKN1A) and p27 (Kip1/CDKN1B) are members of the Cip/Kip family of cyclin-dependent kinase inhibitors, which can induce cell cycle arrest and serve as tumor suppressors. We hypothesized that genetic variants in p21 and p27 may modify individual susceptibility to pancreatic cancer. METHODS: To test this hypothesis, we evaluated the associations of the Ser31Arg polymorphism in p21 and the Gly109Val polymorphism in p27, and their combinations, with pancreatic cancer risk in a case-control study of 509 pathologically confirmed pancreatic adenocarcinoma patients and 462 age- and sex-matched cancer-free controls in non-Hispanic whites. RESULTS: We found that the heterozygous and homozygous variant genotypes combined in a dominant model of the p21 polymorphism were associated with increased risk of pancreatic cancer compared with the homozygous wild type (adjusted odds ratio [ORadjusted], 1.70; 95% confidence interval [CI], 1.13-2.55). This increased risk was more pronounced in carriers with the p27 homozygous wild type (ORadjusted, 2.20; 95% CI, 1.32-3.68) and in nonsmokers (ORadjusted, 2.16; 95% CI, 1.14-4.10), although the p27 polymorphism alone was not associated with pancreatic cancer risk. CONCLUSIONS: These results indicate that the p21 polymorphism may contribute to susceptibility to pancreatic cancer, particularly among p27 homozygous wild-type carriers and nonsmokers.
OBJECTIVES:p21 (WAF1/Cip1/CDKN1A) and p27 (Kip1/CDKN1B) are members of the Cip/Kip family of cyclin-dependent kinase inhibitors, which can induce cell cycle arrest and serve as tumor suppressors. We hypothesized that genetic variants in p21 and p27 may modify individual susceptibility to pancreatic cancer. METHODS: To test this hypothesis, we evaluated the associations of the Ser31Arg polymorphism in p21 and the Gly109Val polymorphism in p27, and their combinations, with pancreatic cancer risk in a case-control study of 509 pathologically confirmed pancreatic adenocarcinomapatients and 462 age- and sex-matched cancer-free controls in non-Hispanic whites. RESULTS: We found that the heterozygous and homozygous variant genotypes combined in a dominant model of the p21 polymorphism were associated with increased risk of pancreatic cancer compared with the homozygous wild type (adjusted odds ratio [ORadjusted], 1.70; 95% confidence interval [CI], 1.13-2.55). This increased risk was more pronounced in carriers with the p27 homozygous wild type (ORadjusted, 2.20; 95% CI, 1.32-3.68) and in nonsmokers (ORadjusted, 2.16; 95% CI, 1.14-4.10), although the p27 polymorphism alone was not associated with pancreatic cancer risk. CONCLUSIONS: These results indicate that the p21 polymorphism may contribute to susceptibility to pancreatic cancer, particularly among p27 homozygous wild-type carriers and nonsmokers.
Authors: Odilia Popanda; Lutz Edler; Peter Waas; Torsten Schattenberg; Dorota Butkiewicz; Thomas Muley; Hendrik Dienemann; Angela Risch; Helmut Bartsch; Peter Schmezer Journal: Lung Cancer Date: 2006-10-23 Impact factor: 5.705
Authors: Simon A Gayther; Honglin Song; Susan J Ramus; Susan Krüger Kjaer; Alice S Whittemore; Lydia Quaye; Jonathan Tyrer; Danielle Shadforth; Estrid Hogdall; Claus Hogdall; Jan Blaeker; Richard DiCioccio; Valerie McGuire; Penelope M Webb; Jonathan Beesley; Adele C Green; David C Whiteman; Marc T Goodman; Galina Lurie; Michael E Carney; Francesmary Modugno; Roberta B Ness; Robert P Edwards; Kirsten B Moysich; Ellen L Goode; Fergus J Couch; Julie M Cunningham; Thomas A Sellers; Anna H Wu; Malcolm C Pike; Edwin S Iversen; Jeffrey R Marks; Montserrat Garcia-Closas; Louise Brinton; Jolanta Lissowska; Beata Peplonska; Douglas F Easton; Ian Jacobs; Bruce A J Ponder; Joellen Schildkraut; C Leigh Pearce; Georgia Chenevix-Trench; Andrew Berchuck; Paul D P Pharoah Journal: Cancer Res Date: 2007-04-01 Impact factor: 12.701
Authors: Kofi Asomaning; Amy E Reid; Wei Zhou; Rebecca S Heist; Rihong Zhai; Li Su; Eunice L Kwak; Lawrence Blaszkowsky; Andrew X Zhu; David P Ryan; David C Christiani; Geoffrey Liu Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Eduardo Schor; Ismael Dale C G da Silva; Hélio Sato; Edmund C Baracat; Manoel João B C Girão; Vilmon de Freitas Journal: Fertil Steril Date: 2008-03-05 Impact factor: 7.329
Authors: Jinyun Chen; Donghui Li; Chongjuan Wei; Subrata Sen; Ann M Killary; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531